Afamelanotide
melanotan I, melanotan-1, MT-1, NDP-alpha-MSH, [Nle4, D-Phe7]-alpha-MSH, CUV1647
Afamelanotide is a stabilised analogue of alpha-melanocyte-stimulating hormone that activates the MC1 receptor on skin melanocytes and increases eumelanin production. It is a genuinely approved medicine, licensed in Europe and the United States as a subcutaneous implant for erythropoietic protoporphyria, a rare disorder in which sunlight causes severe pain. It is the same molecule sold illegally online as 'melanotan I' for cosmetic tanning, but the approved implant and an unregulated vial are not the same product.
Mechanism
Afamelanotide is native alpha-MSH with two substitutions - norleucine at position 4 and D-phenylalanine at position 7 - that block the enzymatic cleavage sites which destroy the natural hormone within minutes and lock the pharmacophore into a more active conformation. The result is a large increase in potency and a far longer duration of action. It is a potent agonist at MC1R, the melanocortin receptor expressed on epidermal melanocytes. MC1R is Gs-coupled: agonism raises cAMP, activates protein kinase A and CREB, and induces MITF, the master transcription factor for the melanogenic enzymes tyrosinase, TYRP1 and DCT. The functional consequence is a switch from red-yellow phaeomelanin towards brown-black eumelanin, which is far more effective at absorbing and scattering light.
In erythropoietic protoporphyria the therapeutic logic is optical rather than metabolic. Afamelanotide does not lower protoporphyrin IX, the accumulated haem precursor that causes the disease. It thickens the pigment filter in the epidermis so that less of the 400-410 nm Soret-band light which excites protoporphyrin IX reaches the dermal capillaries where the reaction occurs. Additional MC1R-mediated antioxidant and anti-inflammatory effects - upregulation of catalase, suppression of NF-kappaB signalling - have been described in cell work and may contribute, but they are not established as the clinical mechanism.
What the research shows
The pivotal evidence is two randomised, double-blind, placebo-controlled trials of the 16 mg implant, given every 60 days, reported together in the New England Journal of Medicine: 74 patients in the European Union and 94 in the United States. Both showed increased pain-free time in direct sunlight, and both show how low the baseline is in this disease. In the European trial, over 270 days, the median duration of pain-free time in direct sunlight was 6.0 hours on afamelanotide versus 0.8 hours on placebo (p=0.005), with fewer phototoxic reactions (77 versus 146, p=0.04). In the US trial, over 180 days and using a different exposure window, it was 69.4 hours versus 40.8 hours (p=0.04). Quality-of-life scores improved in both. Both regulators noted the small sample sizes and the near-impossibility of proper blinding for a drug that visibly tans the patient - a real limitation, since the primary endpoints were patient-reported. Long-term observational data from 115 patients receiving 1,023 implants over up to eight years at two porphyria centres supported durability and tolerability in routine use, with quality-of-life scores rising from about 31% of maximum before treatment to around 74% and holding there; only three patients found it ineffective, though 23% discontinued for reasons unrelated to efficacy.
Outside porphyria the picture thins quickly. In non-segmental vitiligo, a randomised multicentre trial of 55 patients (28 combination, 27 monotherapy) found that afamelanotide added to narrowband UVB produced faster and more extensive repigmentation than narrowband UVB alone, most clearly in Fitzpatrick phototypes IV-VI, but it also caused marked darkening of unaffected skin, and no regulatory approval followed. There is no controlled trial anywhere testing afamelanotide for cosmetic tanning, and none demonstrating that the pigmentation it induces reduces skin cancer risk in healthy people - a claim sometimes made for it that the evidence does not support.
Evidence assessment
High-quality evidence
Two randomised placebo-controlled trials published in the New England Journal of Medicine, plus marketing authorisations from both the EMA and the FDA with approved labelling - though the approval is narrow, the trials were small, blinding was imperfect for a drug that visibly tans the patient, and the EMA licensed it under exceptional circumstances.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Afamelanotide for Erythropoietic Protoporphyria High-quality evidence
Afamelanotide increased median pain-free time in direct sunlight (6.0 vs 0.8 hours over 270 days in the EU trial, p=0.005; 69.4 vs 40.8 hours over 180 days in the US trial, p=0.04), reduced phototoxic reactions in the EU trial, and improved quality of life.
Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria Mixed evidence
Quality-of-life scores rose from 31% to about 74% of maximum and were sustained; only minor adverse events attributable to afamelanotide were recorded, predominantly nausea, and only three patients judged it ineffective.
Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial Mixed evidence
Combination therapy produced statistically significant, faster and more extensive repigmentation than narrowband UVB alone, most clearly in Fitzpatrick phototypes IV-VI, but caused marked darkening of unaffected skin; no regulatory approval for vitiligo followed.
Discovery and development of novel melanogenic drugs. Melanotan-I and -II Preclinical only
Describes the rational design of NDP-alpha-MSH (melanotan I) and the cyclic analogue melanotan II, and the substitutions that confer resistance to enzymatic degradation and increased potency.
Safety
In the trials the commonest adverse effects were nausea, headache, fatigue, back pain and implant-site reactions; nausea is frequent in the first days after implantation and was the predominant adverse effect in long-term observational use. Generalised skin darkening is the intended effect, but it includes darkening of existing moles and freckles, and new naevi have been reported. This is the principal open question. Because MC1R agonism stimulates melanocyte activity and because patients with porphyria may remain on it for years, the licensed product carries a requirement for twice-yearly full skin examination by a clinician. Long-term melanoma risk has not been established either way - the trials were far too small and too short to answer it - and there is a legitimate theoretical concern that induced pigmentation could obscure the visual changes used to detect early melanoma. Efficacy and safety have not been established in children or in pregnancy. None of this safety framework - certification of implanters, structured skin surveillance, batch-controlled manufacture - applies to peptide sold online as 'melanotan I', where the product is injected repeatedly without monitoring and its identity and sterility are unverified.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Authorised across the UK and EU since December 2014 under 'exceptional circumstances' for prevention of phototoxicity in adults with erythropoietic protoporphyria, and available through specialist porphyria centres. Any other supply is unlicensed. The MHRA has issued repeated public warnings against unlicensed melanotan injections sold for tanning and has taken enforcement action against suppliers. |
| United States | FDA-approved 8 October 2019 as a 16 mg bioresorbable subcutaneous implant to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria. It must be inserted by a specifically certified healthcare provider. There is no approved cosmetic or tanning indication anywhere, and the FDA has acted against sellers marketing 'melanotan' products. |
| WADA (sport) | Not specifically named on the WADA Prohibited List. Melanocortin receptor agonists are not currently a listed class. |
Questions
The molecule is the same, but almost nothing else is. The approved product is a sterile 16 mg controlled-release implant, inserted by a certified clinician, supplied to a defined pharmaceutical specification, and accompanied by mandatory twice-yearly skin checks. Vials of 'melanotan I' sold online are unregulated powders of unverified identity and sterility, self-injected repeatedly with no monitoring at all.
No trial has shown that. It increases eumelanin, which does absorb ultraviolet light, and the approved indication is preventing painful phototoxic reactions in a rare metabolic disease - not preventing cancer. Because it also darkens and can change existing moles, there is a competing theoretical concern that it makes early melanoma harder to spot visually. This is precisely why the licensed product requires regular dermatological surveillance.
Because that is the only condition in which randomised evidence of benefit exists. Erythropoietic protoporphyria causes severe burning pain within minutes of sun exposure, and in the European trial the placebo group managed a median of 0.8 hours of pain-free direct sunlight over nine months. Increasing that meaningfully, even modestly in absolute terms, is a real clinical gain for a disease with no other treatment. That reasoning does not transfer to cosmetic tanning in healthy people.
In the licensed regimen the implant is given every two months. The peptide itself has measurable plasma concentrations for roughly five days, but the pigment it induces persists well beyond that because melanogenesis, once switched on, takes weeks to reverse. This is a case where the drug's half-life tells you very little about its duration of effect.